Dianthus Therapeutics Inc DE
For the period ended Sep 30, 2024. Filed Nov 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 7, 2024
DNTH$88.81-1.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Nine Months EndedSeptember 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(56,529) | $(32,992) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation expense | 70 | 47 |
| Stock-based compensation expense | 8,976 | 2,174 |
| Accretion of discount on investment securities | (3,281) | (896) |
| Amortization of right-of-use operating lease assets | 264 | 205 |
| Gain on investment in related party | (307) | — |
| Changes in operating assets and liabilities: | ||
| Receivable from related party | (1,096) | 4,468 |
| Unbilled receivable from related party | (1,109) | 419 |
| Prepaid expenses and other current assets | (428) | 2,546 |
| Other assets | (3,111) | 10 |
| Accounts payable, accrued expenses and operating lease liabilities | 5,911 | (942) |
| Deferred revenue - related party | (96) | (46) |
| Net cash used in operating activities | (50,736) | (25,007) |
| Cash flows from investing activities: | ||
| Capital expenditures | (74) | (100) |
| Purchases of investment securities | (305,628) | (31,195) |
| Proceeds from maturities of investment securities | 42,000 | 59,785 |
| Net cash (used in)/provided by investing activities | (263,702) | 28,490 |
| Cash flows from financing activities: | ||
| Proceeds from exercise of stock options | 614 | 5 |
| Proceeds from the private placement | 229,998 | — |
| Payment of issuance costs in connection with the private placement | (14,665) | — |
| Proceeds from the pre-closing financing | — | 72,000 |
| Payment of issuance costs in connection with pre-closing financing | — | (50) |
| Cash acquired in connection with the reverse recapitalization | — | 69,738 |
| Payment of reverse recapitalization transaction costs | — | (3,254) |
| Proceeds from issuance of promissory notes payable to related party | — | 377 |
| Repayment of promissory notes payable to related party | — | (377) |
| Net cash provided by financing activities | 215,947 | 138,439 |
| (Decrease)/increase in cash, cash equivalents and restricted cash | (98,491) | 141,922 |
| Cash, cash equivalents and restricted cash, beginning of period | 132,391 | 15,425 |
| Cash, cash equivalents and restricted cash, end of period | $33,900 | $157,347 |
| Supplemental Disclosure | ||
| Cash and cash equivalents | $33,671 | $157,282 |
| Restricted cash | 229 | 65 |
| Total cash, cash equivalents and restricted cash | $33,900 | $157,347 |
| Issuance costs in connection with pre-closing financing included in accrued expenses | $— | $4,200 |
| Transaction costs related to reverse recapitalization included in accounts payable and accrued expenses | $— | $710 |
| Conversion of convertible preferred stock into common stock | $— | $118,024 |
| Additions to right-of-use lease assets from new operating lease liabilities | $— | $89 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.